sibenadet

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2011
024620032011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Libraries of dibasic compounds designed around the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™) have… (More)
  • figure 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
2011
2011
Starting with the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™), a number of molecular changes were… (More)
Is this relevant?
2007
2007
AIMS We sought to investigate subject specific QT interval correction factors (SSCF) determined at rest and after exercise and to… (More)
Is this relevant?
2005
2005
In addition to breathlessness and cough, excessive mucus production is one of the main symptoms of chronic obstructive pulmonary… (More)
Is this relevant?
2004
2004
1. Sibenadet (Viozan), a dual dopamine D(2)/beta(2)-adrenoceptor agonist, suppresses histamine-induced tachypnoea in the dog by… (More)
Is this relevant?
2003
2003
The need to manage the key symptoms of chronic obstructive pulmonary disease (COPD) (breathlessness, cough and sputum) is an… (More)
Is this relevant?
2003
2003
Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist, developed specifically to… (More)
Is this relevant?
2003
2003
Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist that has been investigated… (More)
Is this relevant?
2003
2003
In order to identify healthcare resource use patterns associated with chronic obstructive pulmonary disease (COPD), resource… (More)
Is this relevant?
2003
2003
Viozan, (Sibenadet HCl, AR-C68397AA) is a dual D2 dopamine receptor, beta2-adrenoceptor agonist that combines bronchodilator… (More)
Is this relevant?